Evommune's EVO756 misses every AD endpoint, forcing a pipeline reset

The Phase 2b result failed the trial’s core success test. EVO756 missed both the primary and secondary endpoints at every dose, making this a clear below-the-bar read rather than a mixed efficacy result. (Phase 2b trial results)

The atopic-dermatitis opportunity for EVO756 is effectively gone. Evommune said it does not plan to advance the drug in AD, so the failure removes a clinical-stage asset from that indication; its generally favorable tolerability cannot compensate for the lack of efficacy. 〔0〕 (Phase 2b trial results)

The pipeline is being rerouted, not repaired. EVO301 becomes the lead AD program, with a Phase 2b trial planned for mid-2027, while EVO756 remains under evaluation only in migraine prophylaxis. That preserves development optionality, but the replacement program is earlier-stage and does not offset the immediate loss of EVO756’s AD value. (Management commentary)

Cash runway limits the financing urgency but does not soften the clinical setback. Evommune expects its cash, cash equivalents, and investments to fund operations into 2029 under the revised plan, giving it time to pursue the remaining programs. 〔1〕 (Other Events)